My watch list
my.bionity.com  
Login  

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

09-Jan-2018

Evotec AG and APEIRON Biologics AG announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of EUR 3 m will be split equally between the two biotech companies. The success payment was triggered when the partners successfully advanced an undisclosed, novel immuno-oncology small molecule into late-stage pre-clinical development. Under the alliance, the three companies work together to identify small molecule leads and targets for next-generation therapies in immuno-oncology, which may complement the pre-clinical and clinical profiles of leading checkpoint inhibitors.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "The Evotec and APEIRON teams are proud to have achieved our first milestone with Sanofi to discover and develop novel immuno-oncology small molecules therapies. It is a first-in-class approach with tremendous potential in combination with marketed checkpoint inhibitors but also as standalone therapy. The field of immuno-oncology will continue to evolve and at Evotec we will continue to invest in this area."

Dr Hans Loibner, Chief Executive Officer of APEIRON Biologics, said: "We are delighted by the progress made in our collaboration with Evotec and Sanofi. Based on our scientific findings and the mode of action, we jointly agreed to accelerate the research and pre-clinical development of this very promising molecule. The successful achievement of this milestone further demonstrates our abilities to drive innovation in the field of immuno-oncology."

Facts, background information, dossiers
  • Evotec
  • Apeiron Biologics
  • milestone payments
  • immuno-oncology
More about Evotec
  • News

    Evotec and Celgene expand iPSC collaboration to include additional cell lines

    Evotec AG announced that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad rang ... more

    Evotec and Sanofi to develop novel drug candidates from academic research

    Evotec AG announced that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. The BRIDGE LAB031 collaboration enables Evotec to access resources to enter research co ... more

    Evotec and Celgene enter partnership in the field of targeted protein degradation

    Evotec AG announced that Evotec and Celgene Corporation have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec's Panomics platform in order to iden ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec AG

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

More about Apeiron Biologics
  • News

    APEIRON: New CEO announced

    APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO ... more

    Evotec, Apeiron Biologics and Sanofi develop novel cancer immunotherapies

    Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematop ... more

    Apeiron announces start of phase I trail with cellular anti cancer therapy

    Apeiron Biologics AG announced that a first patient has been treated as part of a phase I clinical trial with Apeiron’s individual cellular therapy APN401. The investigator-initiated trial is performed at Wake Forest Baptist Medical Center (WFBMC) led by Pierre L. Triozzi, professor of inte ... more

  • Companies

    APEIRON Biologics AG

    Apeiron Biologics is engaged in the focused development of innovative therapeutics based on validated targets derived from biomedical break-through discoveries. The company, operational since 2005, was founded by Josef Penninger, a top level scientist with high international reputation and ... more

More about Sanofi-Aventis
  • News

    Evotec and Sanofi to develop novel drug candidates from academic research

    Evotec AG announced that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. The BRIDGE LAB031 collaboration enables Evotec to access resources to enter research co ... more

    Sanofi to refocus two global business units

    Sanofi will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets.The company will create a new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabete ... more

    Evotec receives € 3 million payment from Sanofi

    Evotec AG announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec.  This milestone was triggered after Evotec met pre-agreed critical success criteria for a pot ... more

  • Companies

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    sanofi-aventis Groupe

    One of the world's leading pharmaceutical companies and number 1 in Europe. Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: diabetes, oncology, thrombosis, cardiovascular diseases, central nervous system (CNS) and internal medicine. About 100,000 employees worl ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE